New study in Oncology Supportive Care published:
Patients prefer Ectoin^® Mouth Wash over standard treatment (Caphosol^®)

Dortmund/ Hungary, 07.06.2018: bitop is proud to announce that another successful observational study has been conducted with one of its Ectoin^®-containing products. The recently published study compared Ectoin^® Mouth Wash with the standard-of-care calcium phosphate mouthwash Caphosol^® for the treatment of chemotherapy-induced oral mucositis. 80 % of patients using Ectoin^® Mouth Wash were entirely symptom-free after 3 weeks of treatment, compared to only 43 % in the Caphosol^® group. Moreover, Patients preferred Ectoin^® Mouth Wash over calcium phosphate mouthwash. The study shows that Ectoin^® Mouth Wash is tolerable and effective for the treatment of mucositis.

Dr. Zoltán Baráth, Pulmologist at National Korányi Institute of TBC and Pulmology in Budapest worked on the study and states:
“We are very proud that we can now offer cancer patients an innovative and effective treatment for oral mucositis whose efficacy proved to go even beyond the efficacy of the well-known standard treatment Caphosol^®. Taken preventively, we might even protect patients against this painful condition. We are sure that, with Ectoin^® Mouth Wash, we can make life more worth living for cancer patients.”

Here you can download the research paper and the study factsheet.

If you are interested in in-licensing one of bitop's products, please contact us: bd@bitop.de